Advocates flag the limits of the Medicare GLP-1 Bridge

Starting July 1, 2026, some Medicare enrollees will be able to get certain GLP-1 drugs for weight loss through a temporary federal program called the Medicare GLP-1 Bridge Program, which runs through December 31, 2027 ^[1]. The program covers Wegovy (injections and tablets), Zepbound KwikPen, and Foundayo for people 18 and older who meet BMI and health-condition criteria, have Medicare drug coverage, and get prior authorization ^[1]. Enrollees who qualify pay a flat $50 monthly copay ^[1][2].

But the Medicare Rights Center, a nonprofit advocacy group, has flagged several limits on that $50 fee. Because the Bridge Program operates outside the normal Part D benefit, the $50 payment does not count toward a person's Part D deductible or their annual out-of-pocket spending limit ^[1]. The Extra Help program, which normally lowers drug costs for people with limited income and resources, cannot be applied to Bridge Program costs ^[1]. And the $50 fee cannot be paid through Medicare's Prescription Payment Plan, which lets some enrollees spread drug costs into monthly installments ^[1].

The group says these features mean the flat fee "stays the same, no matter what stage of Part D applies" to a person's other drugs ^[1]. For someone who would otherwise qualify for Extra Help and pay very little for a covered prescription, a flat $50 monthly charge for a GLP-1 drug could actually be more expensive than what they'd pay under standard Part D cost-sharing rules ^[1]. The Medicare Rights Center says this makes it important for people to weigh the pros and cons before using the Bridge Program ^[1].

Comments left on the Medicare Rights Center's own site since the announcement illustrate some of the confusion. One commenter, Saul Shapiro, asked how to actually obtain prior authorization after his prescription "gone through the usual channels from pharmacy to Medicare Advantage to (at this point) nowhere" ^[1]. In response, the Medicare Rights Center said the prior authorization process was not yet fully available as of early June and that authorizations would begin processing July 1, 2026 ^[1]. Other commenters described being denied because their qualifying condition, such as sleep apnea, did not independently meet Part D's separate criteria, or because they use a CPAP machine ^[1].

Why it matters for patients

For Medicare enrollees who don't qualify for Extra Help, a flat $50 monthly copay may be a genuine savings compared with a drug's regular list price or standard Part D cost-sharing ^[1]. AARP describes the program as a $50 GLP-1 weight-loss copay option for Medicare enrollees ^[2].

But for beneficiaries who already qualify for Extra Help, the calculation is different. Extra Help normally reduces copays to a few dollars or less, and it cannot be used inside the Bridge Program ^[1]. That means some lower-income enrollees could end up paying more per month through the Bridge Program than they would if the same drug were covered as a standard Part D benefit with Extra Help applied ^[1]. Because the $50 payment also doesn't count toward the Part D deductible or out-of-pocket cap, it does not help a person progress toward catastrophic coverage the way normal drug spending would ^[1].

The Medicare Rights Center is not saying the program has no value. It is pointing out that the tradeoffs depend heavily on a person's individual financial situation, including whether they already receive Extra Help, and that people should understand these tradeoffs before enrolling ^[1].

What happens next

CMS says prior authorizations for the Bridge Program were expected to begin processing on July 1, 2026, with more details on the process promised in the weeks before launch ^[1]. A related, separate initiative — the BALANCE model, which would let Part D plans opt into covering GLP-1 drugs for weight loss — was originally slated to begin in January 2027 but has been delayed indefinitely, according to a CMS announcement in May 2026 ^[1]. The Bridge Program itself is set to run through December 31, 2027, unless further changes are announced ^[1].